These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 20529956)

  • 1. Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation.
    Chaturvedi RK; Calingasan NY; Yang L; Hennessey T; Johri A; Beal MF
    Hum Mol Genet; 2010 Aug; 19(16):3190-205. PubMed ID: 20529956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired PGC-1alpha function in muscle in Huntington's disease.
    Chaturvedi RK; Adhihetty P; Shukla S; Hennessy T; Calingasan N; Yang L; Starkov A; Kiaei M; Cannella M; Sassone J; Ciammola A; Squitieri F; Beal MF
    Hum Mol Genet; 2009 Aug; 18(16):3048-65. PubMed ID: 19460884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease.
    Ho DJ; Calingasan NY; Wille E; Dumont M; Beal MF
    Exp Neurol; 2010 Sep; 225(1):74-84. PubMed ID: 20561979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transducer of regulated CREB-binding proteins (TORCs) transcription and function is impaired in Huntington's disease.
    Chaturvedi RK; Hennessey T; Johri A; Tiwari SK; Mishra D; Agarwal S; Kim YS; Beal MF
    Hum Mol Genet; 2012 Aug; 21(15):3474-88. PubMed ID: 22589249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.
    Weydt P; Pineda VV; Torrence AE; Libby RT; Satterfield TF; Lazarowski ER; Gilbert ML; Morton GJ; Bammler TK; Strand AD; Cui L; Beyer RP; Easley CN; Smith AC; Krainc D; Luquet S; Sweet IR; Schwartz MW; La Spada AR
    Cell Metab; 2006 Nov; 4(5):349-62. PubMed ID: 17055784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
    Jin J; Albertz J; Guo Z; Peng Q; Rudow G; Troncoso JC; Ross CA; Duan W
    J Neurochem; 2013 May; 125(3):410-9. PubMed ID: 23373812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired mitochondrial biogenesis due to dysfunctional adiponectin-AMPK-PGC-1α signaling contributing to increased vulnerability in diabetic heart.
    Yan W; Zhang H; Liu P; Wang H; Liu J; Gao C; Liu Y; Lian K; Yang L; Sun L; Guo Y; Zhang L; Dong L; Lau WB; Gao E; Gao F; Xiong L; Wang H; Qu Y; Tao L
    Basic Res Cardiol; 2013 May; 108(3):329. PubMed ID: 23460046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activating mitochondrial regulator PGC-1α expression by astrocytic NGF is a therapeutic strategy for Huntington's disease.
    Chen LW; Horng LY; Wu CL; Sung HC; Wu RT
    Neuropharmacology; 2012 Sep; 63(4):719-32. PubMed ID: 22633948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mRNA expression levels of PGC-1α in a transgenic and a toxin model of Huntington's disease.
    Török R; Kónya JA; Zádori D; Veres G; Szalárdy L; Vécsei L; Klivényi P
    Cell Mol Neurobiol; 2015 Mar; 35(2):293-301. PubMed ID: 25319408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration.
    Cui L; Jeong H; Borovecki F; Parkhurst CN; Tanese N; Krainc D
    Cell; 2006 Oct; 127(1):59-69. PubMed ID: 17018277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease.
    Johri A; Calingasan NY; Hennessey TM; Sharma A; Yang L; Wille E; Chandra A; Beal MF
    Hum Mol Genet; 2012 Mar; 21(5):1124-37. PubMed ID: 22095692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of SIK2/TORC2 signaling cascade in the regulation of insulin-induced PGC-1alpha and UCP-1 gene expression in brown adipocytes.
    Muraoka M; Fukushima A; Viengchareun S; Lombès M; Kishi F; Miyauchi A; Kanematsu M; Doi J; Kajimura J; Nakai R; Uebi T; Okamoto M; Takemori H
    Am J Physiol Endocrinol Metab; 2009 Jun; 296(6):E1430-9. PubMed ID: 19351809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diabetes medication canagliflozin promotes mitochondrial remodelling of adipocyte via the AMPK-Sirt1-Pgc-1α signalling pathway.
    Yang X; Liu Q; Li Y; Tang Q; Wu T; Chen L; Pu S; Zhao Y; Zhang G; Huang C; Zhang J; Zhang Z; Huang Y; Zou M; Shi X; Jiang W; Wang R; He J
    Adipocyte; 2020 Dec; 9(1):484-494. PubMed ID: 32835596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developmental alterations in motor coordination and medium spiny neuron markers in mice lacking pgc-1α.
    Lucas EK; Dougherty SE; McMeekin LJ; Trinh AT; Reid CS; Cowell RM
    PLoS One; 2012; 7(8):e42878. PubMed ID: 22916173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Energy-sensing factors coactivator peroxisome proliferator-activated receptor γ coactivator 1-α (PGC-1α) and AMP-activated protein kinase control expression of inflammatory mediators in liver: induction of interleukin 1 receptor antagonist.
    Buler M; Aatsinki SM; Skoumal R; Komka Z; Tóth M; Kerkelä R; Georgiadi A; Kersten S; Hakkola J
    J Biol Chem; 2012 Jan; 287(3):1847-60. PubMed ID: 22117073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PGC-1α, mitochondrial dysfunction, and Huntington's disease.
    Johri A; Chandra A; Flint Beal M
    Free Radic Biol Med; 2013 Sep; 62():37-46. PubMed ID: 23602910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease.
    Hathorn T; Snyder-Keller A; Messer A
    Neurobiol Dis; 2011 Jan; 41(1):43-50. PubMed ID: 20736066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-Specific Deletion of PGC-1α from Medium Spiny Neurons Causes Transcriptional Alterations and Age-Related Motor Impairment.
    McMeekin LJ; Li Y; Fox SN; Rowe GC; Crossman DK; Day JJ; Li Y; Detloff PJ; Cowell RM
    J Neurosci; 2018 Mar; 38(13):3273-3286. PubMed ID: 29491012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PGC-1alpha, a new therapeutic target in Huntington's disease?
    McGill JK; Beal MF
    Cell; 2006 Nov; 127(3):465-8. PubMed ID: 17081970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dysfunction of hepatic transcriptional factors in mice with Huntington's Disease.
    Chiang MC; Chern Y; Juo CG
    Biochim Biophys Acta; 2011 Sep; 1812(9):1111-20. PubMed ID: 21651979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.